Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
about
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulantsStroke and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management Across Kidney Disease StagesEuropean Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm SocietyAtrial Fibrillation and Non-cardiovascular Diseases: A Systematic ReviewSynergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry.Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis.Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis.Characteristics of non-valvular atrial fibrillation patients who benefit most from anticoagulation treatmentChronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF TrialsRisk of Ischemic Stroke and Stroke Prevention in Patients with Atrial Fibrillation and Renal Dysfunction.European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation.Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.Antithrombotic medications in dialysis patients: a double-edged sword.Atrial fibrillation and chronic kidney disease: struggling through thick and thin.Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease.Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin.Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study.Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis.Relationship between renal function and circulating microparticles, soluble P-selectin and E-selectin levels in atrial fibrillation.Warfarin Use and Increased Mortality in End-Stage Renal Disease.Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Con.Navigating the choice of oral anticoagulation therapy for atrial fibrillation in the NOAC era.The impact of co-morbidity burden on appropriate implantable cardioverter defibrillator therapy and all-cause mortality: insight from Danish nationwide clinical registers.Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management.Renal Dysfunction, CHADS2 Score, and Adherence to the Anticoagulant Treatment in Nonvalvular Atrial Fibrillation.Risk of stroke and bleeding in patients with heart failure and chronic kidney disease: a nationwide cohort study.Decreased Renal Function Is Associated with Elevated CHA2DS2VASC and R2CHADS2 Scores in Non-Valvular Atrial Fibrillation Patients Presenting with Stroke.Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry.Anti-thrombotic therapy for atrial fibrillation in patients with chronic kidney disease: Current views.[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).Balancing Anticoagulation Decisions in Patients on Dialysis with Atrial Fibrillation.Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 studyChronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceOral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial FibrillationIncidence and prognostic implications of late bleeding events after percutaneous mitral valve repair
P2860
Q26781181-9B4442A9-5BFA-4E45-AE0D-7D7E8CAB3DB6Q26782013-8914ECB2-65C4-468A-8B69-DB79B68C7078Q26796261-DDD4B269-78E7-4287-A041-C63FEE2B8772Q28082470-3D43BE1F-76B8-4825-8631-9F30D0F2FCDEQ33720574-AD1032F4-6108-46F7-8B46-FC2C668B9FDBQ36069462-4ACFC533-BD5D-4B55-8CD1-198E69EE6B71Q36171135-9CF3E370-7AD0-4698-A8F9-74005F5AF254Q36411967-47FA2A83-31F4-482A-BD19-87F16C092624Q37035168-A91084A0-B73B-4A9B-8B41-E5BF35EF52C4Q37468787-562EFD17-3964-4126-B362-D9E16DA9E910Q38571627-067B1ACA-AE57-464B-B841-DBBA475F1A43Q38647787-ED2BDBC5-EB51-453A-AC8F-00C44FE20774Q38821650-C48403DF-03AC-4082-B03F-B256967B4531Q38918821-80622027-5A0B-4A7D-AD1A-BBC48D2E3F7BQ38981275-D3319941-C86C-41E6-A810-140727EE5557Q39000809-8151A7E9-AE6D-4F3F-9D9C-44838C71A3C4Q39232066-262A6FD1-1633-4725-991B-47489480336DQ39864511-C8E5FECF-5A21-44AF-BD1B-B2355FFAD2BAQ40142501-6A5C00F7-92A6-4D64-9AFD-E90086F198BBQ40480109-7BC0DA36-BD1F-422B-8B66-DBE90B1D89CAQ41182747-22417CD2-E5E7-459B-80CB-6F63A74C2659Q41964553-0187D3DF-9654-4298-B107-182E3CD21222Q44463959-4FC22535-18EF-4550-9A7A-B3800565A7A5Q44928316-EED0300B-0653-4E60-9EB9-66E756C01F6BQ47135358-14282DF1-EC27-4F28-9BBD-19F5AECC6433Q47863626-CC68C4AD-5364-423B-BFBE-9338689BBB67Q47920228-98600C00-6F4D-4093-B0F6-F80DE7E1260AQ48522473-1B8A7479-B8A0-493B-BC1B-DD2EB0777975Q48932827-3E429B26-279E-4B84-8A98-5CF85AB7A1AEQ49565170-794C0C7C-C7F6-4C84-95F4-2835F675DD0FQ49724516-37778105-0895-4FA4-A2A1-139302D3D2D8Q49820824-1A0AF235-47F8-48F9-BE06-863C651EC284Q50075292-5BEA7728-71ED-4461-8337-731810AE7C17Q52840065-9AED4B07-02E7-4573-84C6-2759DAD8116FQ55476982-4E1D3C63-42C1-43E2-9AAA-72D68F89FB8DQ55522399-FEA91830-83A5-47BA-9F4A-4D85678DFFEDQ57625963-A2457A95-8DFB-410E-81BB-B8B1E7CF8100Q57750151-0026E47F-A77F-47C1-AC79-F1A987082C8DQ58578133-2DA9BFBC-2B1C-4834-B5E9-45D84C628C8EQ58718637-CDA02E4A-F03A-4E6C-AA59-C615E5D8E8E2
P2860
Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Net clinical benefit of antith ...... de observational cohort study.
@en
type
label
Net clinical benefit of antith ...... de observational cohort study.
@en
prefLabel
Net clinical benefit of antith ...... de observational cohort study.
@en
P2093
P50
P1476
Net clinical benefit of antith ...... de observational cohort study.
@en
P2093
Kristine Hommel
Morten Lamberts
Morten Lock Hansen
P304
P356
10.1016/J.JACC.2014.09.051
P407
P50
P577
2014-12-01T00:00:00Z